Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2017
At a glance
- Drugs Alisertib (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 29 Nov 2017 Planned End Date changed from 1 Dec 2021 to 15 Dec 2021.
- 29 Nov 2017 Planned primary completion date changed from 1 Dec 2021 to 15 Dec 2021.
- 10 Jul 2017 Status changed from not yet recruiting to recruiting.